Surgical experiences of intraductal papillary mucinous neoplasms of the pancreas at a single Japanese institute: characteristics of malignant histology.

Author(s)
Nanashima, Atsushi; Sumida, Yorihisa; Abo, Takafumi; Oikawa, Masahiro; Takeshita, Hiroaki; Hidaka, Shigekazu; Sawai, Terumitsu; Yasutake, Toru; Kinoshita, Naoe; Hayashi, Tomayoshi; Nagayasu, Takeshi

Citation
Hepato-gastroenterology, 55(88), pp.2238-2241; 2008

Issue Date
2008-11

URL
http://hdl.handle.net/10069/22652

Copyright 2008 Thieme Publishing
Original Papers

Surgical experiences of intraductal papillary mucinous neoplasms of the pancreas at a single Japanese institute: Characteristics of malignant histology

Atsushi Nanashima, MD, Yorihisa Sumida, MD, Takafumi Abo, MD,
Masahiro Oikawa, MD, Hiroaki Takeshita, MD, Shigekazu Hidaka, MD,
Terumitsu Sawai, MD, Toru Yasutake, MD, Naoe Kinoshita, MD,*
Tomayoshi Hayashi, MD,* Takeshi Nagayasu, MD

Division of Surgical Oncology and *Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan

Running title: Characteristics in malignant IPMN

Corresponding and reprint requests to: Atsushi Nanashima, M.D.
Division of Surgical Oncology, Department of Translational Medical Sciences,
Nagasaki University Graduate School of Biomedical Sciences,
1-7-1 Sakamoto, Nagasaki 852-8501, JAPAN
Tel.: +81-95-819-7304, Fax: +81-95-819-7306
E-mail: a-nanasm@alpha.med.nagasaki-u.ac.jp
ABSTRACT

Background/Aims: Characteristics of intraductal papillary mucinous neoplasms of pancreas (IPMN) have been clarified by a worldwide survey and meeting. However, the malignant behavior or prognosis of the disease is not always uniform.

Methodology: We examined the clinicopathologic demographics, surgical records and outcome according to degree of histologic malignancy in 18 IPMN patients between 1994 and 2006.

Results: Main duct type was observed in 3 patients, branch duct type in 6, and mixed type in 9. Eight of 18 patients (44.4%) had other malignancies, and other synchronous tumors were observed in the adenoma group. CA 19-9 was increased in invasive carcinomas. The size of the main pancreatic duct and cysts were not correlated with degree of malignancy. Mural nodules were more frequently observed in minimally invasive and invasive carcinomas. Segmental resection or observation was selected in the adenoma group; however, combined resection of main vessels was performed in invasive carcinoma groups. Although 3 of 5 patients with invasive carcinomas had a recurrence and poor patient prognosis, recurrence was not observed in other groups.

Conclusions: Surgical results for IPMN were satisfactory; however, it is necessary to determine the operative indication before the carcinoma becomes invasive as such lesions have a poor prognosis.

KEYWORDS: intraductal papillary mucinous neoplasms, pancreas, invasiveness

ABBREVIATIONS: intraductal papillary mucinous neoplasms (IPMN), intraductal papillary mucinous carcinomas (IPMC)
INTRODUCTION

Intraductal papillary mucinous neoplasms (IPMN) include the pancreatic diseases such as precancerous lesions, carcinoma in situ, and non-invasive or invasive advanced carcinomas, which are classified into three types: branch, main and mixed duct type (1, 2). This disease has been fully understood worldwide, and recently, the International consensus guidelines for management of IPMN of the pancreas were published (3). However, the malignant behavior or prognosis of the disease is not always uniform in each case. Some reports emphasize the importance of examination of histologic type difference (4-5) and the malignant characteristics of IPMN have not been fully clarified. Therefore, it is still necessary to examine the characteristics associated with the degree of histological malignancy or patient outcomes at this stage. In the present report, to clarify characteristics, we examined the clinical demographics, pathological data and outcome in 18 IPMN patients at a single Japanese institute.

METHODOLOGY

Definition and Pathological Diagnosis of IPMN

In the present study, IPMN was classified as main duct IPMN or branch duct IPMN, based on the histological diagnosis (3). The definition of main duct type was when the size of the main pancreatic duct was more than 5 mm. However, lesions in patients who did not undergo resection were diagnosed by image diagnosis. All patients underwent enhanced computed tomography, magnetic resonance image, endoscopic ultrasonography or endoscopic retrograde pancreatography for preoperative diagnosis.

We analyzed 18 patients with IPMN who did or did not undergo surgical resection in the Division of Surgical Oncology, Nagasaki University Graduate School of Biomedical
Sciences (NUGSBS), and its related hospitals between 1996 and 2006. The study design was approved by the Human Ethics Review Board of our institution. Informed consent for data collection was obtained from each patient during this period. Anesthetic and patient data were retrieved in the NUGSBS database. Tumor stage and curability were determined according to the second English edition of Classification of Pancreatic Carcinoma (6). Definition and criteria were followed by the International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas (3). Subjects were divided into four groups by histologic classification: 1) Adenoma including borderline atypia in 6 patients, 2) non-invasive in 3, 3) minimally invasive carcinomas in 4 and 4) invasive carcinomas in 5.

Statistical Analysis

Data from different groups were compared using one-way analysis of variance (ANOVA) and examined by Student’s t-test and categorical data were analyzed by the Fisher’s exact test. A two-tailed P value of < 0.05 was considered significant. Statistical analyses were performed using SAS software (Statistical Analysis System Inc., Cary, NC).

RESULTS

Patients included 12 men and 6 women aged 49-81 years old (mean 69.9±11.1) (Table 1). IPMN lesions were in the pancreas head in 13 patients, body in 2, and tail in 4. One patient had 2 IPMN, 1 in the head and 1 in the tail. IPMN lesions were not significantly different between the 4 histologic groups. Carcinoma of IPMN (IPMC) was main duct type in 2 patients, branch duct type in 1, and mixed type in 9. Most cases of
IPMC were main duct type or mixed type, and therefore, branch type was dominant in adenoma of IPMN. Diabetes and hypertension were frequently associated with IPMN patients. Eight of 18 patients (44.4%) had other malignant neoplasms, which were observed in each histologic group. Synchronously accompanying malignant tumors were observed only in the group of adenoma. Preoperative tumor markers such as CEA and CA 19-9 were increased in minimally invasive and invasive carcinomas. One patient in the adenoma group showed increased levels of CA 19-9; however, this increase might have been influenced by associated gallbladder carcinoma.

The size of the main pancreatic duct or cyst size was not correlated with degree of malignancy (Table 2). Mural nodule was more frequently observed in minimally invasive and invasive carcinomas, but not in adenomas. Operative procedures were not significantly different between groups; however, segmental resection or observation was selected in the adenoma group. On the other hand, combined resection of surrounding main vessels was performed in the invasive carcinoma group because of direct vascular involvement. In groups of adenoma, non-invasive and invasive carcinomas, recurrence of IPMN was not observed. Hence, 3 of 5 (60%) patients with invasive carcinomas had a severe tumor recurrence, which led to a poor patient prognosis. Two other patients with invasive carcinoma showed long-term survival without tumor recurrence. Regardless of being tumor recurrence-free, 3 patients died and 2 died from other malignant diseases at an early period after operation for IPMN in adenoma, non-invasive and minimally invasive carcinoma groups.
DISCUSSION

IPMN is an established concept and therefore diagnostic and treatment criteria are similar worldwide (3). Surgical removal of this disease is the only curable treatment (7). In the present study, we compared clinical parameters in each degree of histological malignancy according to the international consensus guidelines (3). Based on the report by Tanaka et al., most cases of branch type IPMN showed benign neoplasm (8); however, in our series 1 of 12 IPMC cases were branch type, which was located in the pancreatic uncus. Previous reports reported the relationship of IPMN and other concomitant malignant neoplasm (9). In the present study, concomitant neoplasm was frequent as well, particularly in adenoma patients. Genetic instability may be associated with this multiple carcinogenesis (10). CA19-9 is a useful predictive marker of pancreatic or biliary carcinomas (11); however, the usefulness of CA19-9 as a predictor of malignant behavior in IPMN has not been clarified to our knowledge. In our series, an increase of CA19-9 was rarely observed, even in minimally invasive IPMC. An increase in CA19-9 value was thought to predict invasiveness of IPMC preoperatively.

The surgical indication of IPMN is based on the size of the main pancreatic duct, presence of a cyst in branch type, or presence of mural module in the duct (3, 12). Our criteria of surgical resection for IPMN has been main pancreatic duct >5 mm, peripheral cysts >30 mm or presence of mural nodule. Some reports have indicated the necessity of resection in smaller cysts <30 mm because of the malignant potential (13, 14). Schmidt et al. reported that predictors of malignant and invasive pathology of IPMN were mainly pancreatic duct diameter (more than or equal to 6 mm), multiple side branch lesions and the presence of mural nodules; however, branch size, location and distribution of lesion were not related to invasiveness (14). At this stage, however, it is still difficult to judge
the malignancy of small lesions of branch type IPMN using the available diagnostic
tools. Careful follow-up seems to be better in branch type IPMN with small cysts <30
mm without mural nodules to avoid unnecessary resection, because the possibility of
operative risk with limited resection of the pancreas is not low (15). In the present series,
the size of the main pancreatic duct or cyst size was not significantly associated with the
malignant histologic degree; however, the presence of mural nodule was correlated with
degree of histological malignancy. This factor is the most reliable predictor for the
diagnosis of invasive IPMC. Most cases underwent major pancreatic resection such as
pancreatecojejunostomy or distal pancreatectomy because of the tumor location, size
and difficulty of preoperative determination of malignancy or invasiveness of IPMN, as
in other reports (16, 17). IPMN often spreads along the epithelium of the pancreatic duct
(18), which is a serious problem in the decision of whether to resect the stump of the
pancreas. Total pancreatectomy is often performed based on other reports (19).

Postoperative outcomes in adenoma, non-invasive carcinoma and minimally
invasive carcinoma of IPMN were satisfied in our results. Unfortunately, 3 patients died
of other diseases. Previous reports also indicated good long-term IPMN outcomes
without invasiveness after complete resections (14, 20). Based on these degrees of
histological malignancy, surgical resection is strongly recommended at this stage.
Occurrence or simultaneous presence of other malignant lesions should be followed, as
these sometimes influence prognoses (21). On the other hand, in invasive IPMC,
combined resection of the surrounding main vessel was necessary in two cases; however,
the prognosis was extremely poor in 3 of 5 patients. Adjuvant chemotherapy or
brachiotherapy is necessary to improve the prognosis (22). Our results indicate that the
treatment strategies for invasive IPMC should be considered the same as those for
advanced tubular adenocarcinomas of the pancreas (23). Recent reports showed better patient prognoses in invasive IPMN in comparison with those in tubular adenocarcinomas of the pancreas (14, 24, 25). Our result also showed a good long-term prognosis in 2 patients with invasive IPMN. The surgical benefits for invasive IPMN still require further examination, and future work in a larger number of cases is necessary.

In conclusion, we examined 18 patients with IPMN including 17 who underwent surgical treatment. Surgical removal of the disease provided a good prognosis in adenoma, non-invasive carcinoma and minimally invasive carcinoma cases of IPMN. However, careful management of combined malignant neoplasms is necessary. Aggressive surgical resection for invasive IPMN improves the long-term prognosis, and, furthermore, adjuvant anti-cancer treatment is expected to improve patient survival.

REFERENCES


adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007 1;140:31-35.


17 Sugiura H, Kondo S, Islam HK, Ito K, Ono K, Morikawa T, Okushiba S, Katoh H: Clinicopathologic features and outcomes of intraductal papillary-mucinous tumors of


22 Garofalo MC, Regine WF, Tan MT: On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg. 2006;244:332-333.


Table 1. Preoperative patient demographics according to degree of malignancy

<table>
<thead>
<tr>
<th>Age (years), Gender</th>
<th>Lesions</th>
<th>Duct type</th>
<th>Accompanied disease</th>
<th>History of other cancer</th>
<th>CEA (ng/mL; N&lt;3.0)</th>
<th>CA19-9 (U/mL; N&lt;37)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adenoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>77y male</td>
<td>tail</td>
<td>branch</td>
<td>—</td>
<td>2.2</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>2</td>
<td>60y male</td>
<td>body</td>
<td>branch</td>
<td>—</td>
<td>1.0</td>
<td>13.1</td>
</tr>
<tr>
<td>3</td>
<td>78y female</td>
<td>body</td>
<td>main</td>
<td>DM, HT</td>
<td>2.5</td>
<td>3.2</td>
</tr>
<tr>
<td>4</td>
<td>69y male</td>
<td>head</td>
<td>branch</td>
<td>—</td>
<td>1.3</td>
<td>35.2</td>
</tr>
<tr>
<td>5</td>
<td>75y female</td>
<td>head</td>
<td>mixed</td>
<td>HT</td>
<td>2.1</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>79y female</td>
<td>head</td>
<td>branch</td>
<td>Arrhythmia</td>
<td>3.4</td>
<td>137</td>
</tr>
<tr>
<td><strong>Non-invasive carcinomas</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>79y female</td>
<td>head</td>
<td>mixed</td>
<td>HT</td>
<td>1.7</td>
<td>18</td>
</tr>
<tr>
<td>8</td>
<td>72y male</td>
<td>head</td>
<td>main</td>
<td>—</td>
<td>2.7</td>
<td>14.2</td>
</tr>
<tr>
<td>9</td>
<td>49y male</td>
<td>tail</td>
<td>mixed</td>
<td>—</td>
<td>1.5</td>
<td>19.9</td>
</tr>
<tr>
<td><strong>Minimally invasive carcinomas</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>70y male</td>
<td>head</td>
<td>mixed</td>
<td>—</td>
<td>2.1</td>
<td>9.8</td>
</tr>
<tr>
<td>11</td>
<td>64y male</td>
<td>head &amp; tail</td>
<td>mixed</td>
<td>HT</td>
<td>2.2</td>
<td>77.2</td>
</tr>
<tr>
<td>12</td>
<td>59y male</td>
<td>head</td>
<td>mixed</td>
<td>DM, HT</td>
<td>1.5</td>
<td>52</td>
</tr>
<tr>
<td>13</td>
<td>77y male</td>
<td>head</td>
<td>main</td>
<td>HT, Tuberculosis</td>
<td>1.7</td>
<td>12</td>
</tr>
<tr>
<td><strong>Invasive carcinoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>59y male</td>
<td>head</td>
<td>branch</td>
<td>—</td>
<td>6.3</td>
<td>809.5</td>
</tr>
<tr>
<td>15</td>
<td>79y male</td>
<td>head</td>
<td>mixed</td>
<td>DM</td>
<td>2.9</td>
<td>131.9</td>
</tr>
<tr>
<td>16</td>
<td>71y female</td>
<td>head</td>
<td>mixed</td>
<td>—</td>
<td>1.2</td>
<td>30.6</td>
</tr>
<tr>
<td>17</td>
<td>61y male</td>
<td>head</td>
<td>mixed</td>
<td>HT</td>
<td>165</td>
<td>182.6</td>
</tr>
<tr>
<td>18</td>
<td>81y female</td>
<td>tail</td>
<td>mixed</td>
<td>HT</td>
<td>1.5</td>
<td>15.2</td>
</tr>
</tbody>
</table>

DM; diabetes mellitus, HT; hypertension, *; synchronous diseases, Ca.; carcinomas, N; normal
Table 2. Surgical and pathological data, and patient outcomes

<table>
<thead>
<tr>
<th>Size of main duct (mm)</th>
<th>Size of cyst (mm)</th>
<th>Mural nodule</th>
<th>Operation</th>
<th>Tumor recurrence</th>
<th>Prognosis (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>No</td>
<td>DP</td>
<td>No</td>
<td>Survival (21)</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>No</td>
<td>SR</td>
<td>No</td>
<td>Survival (78)</td>
</tr>
<tr>
<td>3</td>
<td>12</td>
<td>No</td>
<td>DP</td>
<td>No</td>
<td>Died from uterine ca. (10)</td>
</tr>
<tr>
<td>4</td>
<td>5</td>
<td>No</td>
<td>PPPD</td>
<td>No</td>
<td>Survival (50)</td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>No</td>
<td>PPPD</td>
<td>No</td>
<td>Survival (22)</td>
</tr>
<tr>
<td>6</td>
<td>3</td>
<td>No</td>
<td>observation</td>
<td>—</td>
<td>Died from gallbladder ca. (14)</td>
</tr>
<tr>
<td>7</td>
<td>10</td>
<td>No</td>
<td>PPPD</td>
<td>No</td>
<td>Survival (79)</td>
</tr>
<tr>
<td>8</td>
<td>20</td>
<td>Yes</td>
<td>PD</td>
<td>No</td>
<td>Survival (51)</td>
</tr>
<tr>
<td>9</td>
<td>8</td>
<td>No</td>
<td>DP</td>
<td>No</td>
<td>Survival (8)</td>
</tr>
<tr>
<td>10</td>
<td>9</td>
<td>No</td>
<td>PD</td>
<td>No</td>
<td>Survival (44)</td>
</tr>
<tr>
<td>11</td>
<td>7</td>
<td>No</td>
<td>PPPD+DP</td>
<td>No</td>
<td>Died from pneumonia (84)</td>
</tr>
<tr>
<td>12</td>
<td>10</td>
<td>Yes</td>
<td>PPPD</td>
<td>No</td>
<td>Survival (40)</td>
</tr>
<tr>
<td>13</td>
<td>5</td>
<td>Yes</td>
<td>PPPD</td>
<td>No</td>
<td>Survival (8)</td>
</tr>
<tr>
<td>14</td>
<td>4</td>
<td>Yes</td>
<td>PPPD+SMV resection</td>
<td>Liver metastasis (8M)</td>
<td>Cancer death (12)</td>
</tr>
<tr>
<td>15</td>
<td>12</td>
<td>Yes</td>
<td>PD</td>
<td>No</td>
<td>Survival (61)</td>
</tr>
<tr>
<td>16</td>
<td>17</td>
<td>No</td>
<td>PPPD</td>
<td>Peritonitis carcinomatosa (41M)</td>
<td>Cancer death (43)</td>
</tr>
<tr>
<td>17</td>
<td>8</td>
<td>Yes</td>
<td>PD+PV resection</td>
<td>Liver metastasis (1M)</td>
<td>Cancer death (4)</td>
</tr>
<tr>
<td>18</td>
<td>9</td>
<td>Yes</td>
<td>DP</td>
<td>No</td>
<td>Survival (24)</td>
</tr>
</tbody>
</table>

(SR; segmental resection, DP; distal pancreatectomy, PPPD; pylorus preserving pancreatoduodenectomy, PD; pancreatoduodenectomy, SMV; superior mesenteric vein, PV; portal vein, ca.; carcinomas)